Browse Tag

Insomnia

January 23, 2020

Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan

Eisai Co., Ltd. announced today that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered orexin receptor antagonist DAYVIGO (2.5mg, 5mg, and 10mg tablets, lemborexant) for treatment of insomnia. DAYVIGO is a dual orexin receptor antagonist that inhibits orexin

March 2, 2021

New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong

Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong)

Pharmaceutical News

New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong

March 2, 2021

Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered

Pharmaceutical News

Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan

January 23, 2020

Eisai Co., Ltd. announced today that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered

Go toTop